Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 9

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 9
---
 Minimum Stockholders’ Equity Rule.

The Notification Letter has
no immediate effect on our listing on The Nasdaq Capital Market at this time, nor are our business operations affected by receipt of the
Notification Letter. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days, or until December 18, 2025, to submit
a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from receipt of the Notification
Letter to evidence compliance.

We are looking into various
options available to regain compliance and maintain our continued listing on The Nasdaq Capital Market. There can be no assurance that
our plan will be accepted or we will be able to regain compliance with the Minimum Stockholders’ Equity.

As previously announced, on
September 17, 2025, we entered into securities purchase agreements (the “SPAs”) with investors (the “CLA Investors”)
pursuant to which we shall issue and sell, from time to time, convertible promissory notes (the “Promissory Notes”) in the
aggregate principal amount of up to $10,000,000 (the “Subscription Amount”). As of the date hereof, we have issued Promissory
Notes in the aggregate principal amount of $2.5 million, of which an aggregate of $2.2 million of outstanding amounts due under the Promissory
Notes were converted into 4,135,000 Common Shares. In addition, on November 13, 2025, we raised approximately $0.788 million in a registered
direct offering of common shares and pre-funded warrants (see “Recent Developments—First November 2025 Registered Direct Offering”
below for additional information), on November 17, 2025, we raised approximately $1.377 million in a registered direct offering of common
shares and pre-funded warrants (see “Recent Developments—Second November 2025 Registered Direct Offering” below for
additional information), and as of the date hereof, we issued 2,090,987 common shares as a result of the exercises for cash and on a cashless
basis of warrants to purchase 2,894,769 common shares, which were previously classified as a liability given certain of their contractual
terms which precluded equity classification, that were issued in our financings in in April 2023 and January 2024 for aggregate gross
proceeds of approximately $183,000 (see “Recent Develop